Status: Ongoing
First registered on:
02/08/2019
Last updated on:
02/08/2019
1. Study identification
EU PAS Register NumberEUPAS30772
Official titleImpact of Rotavirus Vaccination on Acute Gastroenteritis outpatient and emergency department visits using “Real World Data” from the Valencia Region, Spain
Study title acronym
Study typeObservational study
Brief description of the studyAcute gastroenteritis is a frequent disease, with rotavirus being the main cause in children under 5 years of age. Every year, RV accounted for 231 deaths, more than 87,000 hospitalisations, and nearly 700,000 outpatient visits in Europe. In addition to the clinical impact, these rotavirus-associated events result in increased medical expenses, lost productivity, and other costs to society and families.
In Spain, rotavirus vaccines have been available since 2006 (RV1) and 2007 (RV5). Benefits of rotavirus vaccines have been widely studied. These kind of studies in Spain have separately, and for varied populations and time periods, analysed vaccines impact on RVAGE-hospitalizations (up to 71% reduction in infants), all-cause AGE hospitalizations (up to 39% reduction in infants) (11) and effectiveness (over 85% effective against rotavirus hospitalization among young children). The effects of rotavirus vaccine on ED and outpatients visits are not widely documented.
This study aims to provide for the first time a comprehensive evaluation of the impact of rotavirus vaccines on ED and outpatient utilization among children <5 years of age of the Valencia Region, for acute gastroenteritis. This approach will provide estimates of the economic impact of rotavirus vaccines on outpatients and ED visits and the national health system associated costs. The Valencia Region accounts with a network of health care databases linked together, which allow the linkage of ED and outpatients registries with the vaccine status at individual level.
Secondary objectives:
- To estimate the risk of AGE-O and AGE-ED consultations between vaccinated and nonvaccinated children aged less than 5 years from the Valencia Region.
- To estimate the economic impact of rotavirus vaccines on AGE-O and AGE-ED visits and the national health system associated costs among children aged less than 5 years from the Valencia Region.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameFISABIO
Centre locationValencia
Details of (Primary) lead investigator
Title Dr
Last name Orrico-Sánchez
First name Alejandro
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Spain
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed28/11/2018
Start date of data collection28/12/2018
Start date of data analysis28/07/2019
Date of interim report, if expected
Date of final study report28/07/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesMSD100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Orrico-Sánchez
First name Alejandro
Address line 1Avenida Cataluña 21
Address line 2
Address line 3
CityValencia
Postcode
CountrySpain
Phone number (incl. country code)0034961925980
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Orrico-Sánchez
First name Alejandro
Address line 1Avenida Cataluña 21
Address line 2
Address line 3
CityValencia
Postcode
CountrySpain
Phone number (incl. country code)0034961925980
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)Yes
Gastroenteritis rotavirus
8. Population under study
Age
Children (2 - 11 years)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects600000
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
Exposure registry
11. Scope of the study
What is the scope of the study?
Post-licensure vaccination impact study
Primary scope : Post-licensure vaccination impact study
12. Main objective(s)
What is the main objective of the study?
To estimate the impact of rotavirus vaccination on all-cause acute gastroenteritis outpatient (AGE-O) and Emergency Department (AGE-ED) consultations among children aged less than 5 years from the Valencia Region.
Are there primary outcomes?Yes
1- AGE-O: all-cause acute gastroenteritis outpatients visits.
2- AGE-ED: all-cause acute gastroenteritis emergency department visits.
3- AGE-O or AGE-ED: all-cause acute gastroenteritis outpatient and emergency department visits.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Observational retrospective study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Inclusion in the study: 1st January 2009 if the subject was continuously registered in PHS for at least 6 months before this date and was aged less tan 5 years old,or first date after 1st January2009 when the subject was continuously registered for at least 6 months before this date and was under 5 years old. Follow up ended when they left Valencia, they death at the end of the study.
15. Data analysis plan
Please provide a brief summary of the analysis method
A descriptive analysis will be developed, yearly outpatients and ED rates will be calculated as the number of AGE-O or AGE-ED visits divided by the total population by gender, age, health department and in general.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
